Earnings

Fulcrum Reports Narrower Third-Quarter 2026 Net Loss Ahead of Planned Slate Merger

The Tip Desk · November 13, 2026 · 4 min read

Research and development expense fell to $3.0 million in the three months ended September 30, 2026, as the company wound down pociredir and cut its workforce 85%.

Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company, reported a net loss of $10.9 million for the three months ended September 30, 2026, compared with $19.6 million a year earlier, as research and development expense fell to $3.0 million from $14.3 million. The company entered a merger agreement with Slate Medicines on August 16, 2026, after discontinuing its pociredir program for sickle cell disease and cutting its workforce by about 85%. The transaction is expected to close in the fourth quarter of 2026 and is intended to qualify as a tax-free reorganization.

The company said it expects to account for the deal as an in-substance reverse recapitalization of Fulcrum by Slate. If it closes, Fulcrum will continue as the surviving corporation under the name Slate Medicines, Inc., with Slate’s management taking over and the combined company expected to pursue Slate’s business activities. Slate concluded that any acquired in-process research and development assets of Fulcrum would be de-minimis and would not be further pursued.

In connection with the closing, Fulcrum expects to declare a cash dividend of $275 million in the aggregate to pre-merger stockholders, subject to adjustment under the merger agreement. The registration statement on Form S-4 was declared effective on November 4, 2026, but the merger remains subject to stockholder approval and other closing conditions. Upon termination under specified circumstances, Fulcrum may owe Slate a $10 million termination fee; in certain other circumstances, Slate may owe Fulcrum $15 million.

The quarter’s reported results reflected the wind-down that preceded the deal. Research and development expense fell to $3.0 million in the three months ended September 30, 2026, from $14.3 million a year earlier. The company said the decrease was primarily due to $6.3 million of lower external research and development costs from the wind-down of pociredir clinical activities and termination of early-stage development, $3.1 million of lower employee compensation from decreased headcount, $1.1 million of lower facility costs, and $0.5 million of lower laboratory supplies.

General and administrative expenses were $8.4 million, up from $7.6 million a year earlier, as professional services rose $2.2 million, primarily on higher legal costs, and other costs rose $0.4 million, partly offset by $1.9 million of lower employee compensation. Impairment of long-lived assets was $2.2 million, related to writing down the operating lease right-of-use asset at 26 Landsdowne Street after a September 2026 lease-termination agreement that ends the lease December 31, 2026. Restructuring expenses were $0.2 million, after the May 31, 2026 restructuring was substantially completed in the second quarter. Other income, net was $2.9 million.

The company said it has ceased active research and development and expects those expenses to decline significantly in future periods. It also said it expects to incur restructuring charges, long-lived asset impairment charges, and professional and advisory fees in connection with the merger, a considerable portion of which will be incurred regardless of whether the merger completes.

Cash, cash equivalents, and marketable securities were $306.5 million as of September 30, 2026, down from $318.8 million as of June 30, 2026. Fulcrum said that balance will fund operating expenses and capital expenditures for at least the next 12 months from the date of the quarterly report. It has not generated product revenue and, following the pociredir discontinuation, does not expect product-sales revenue unless it resumes research and development.

On November 7, 2026, Fulcrum and Slate entered an asset purchase agreement to sell Fulcrum’s early-stage HbF assets to an unaffiliated third-party pharmaceutical company for about $7.0 million in cash. Closing is contingent on consummation of the merger, or on necessary approvals if the merger agreement is terminated. The company said proceeds are expected to be funded into escrow before the merger closing, credited to net cash for purposes of the merger agreement, and used to increase the cash dividend.

The company said it does not anticipate using its $100 million at-the-market offering program pending consummation of the merger. Future funding requirements, it said, will depend on the outcome, timing and costs of the merger, including payment of the cash dividend, cash outflows to complete the restructuring, ongoing public-company costs, and, if the merger does not close, the costs of a potential dissolution and liquidation or a resumption of independent research and development.